Compile Data Set for Download or QSAR
maximum 50k data
Found 228 Enz. Inhib. hit(s) with all data for entry = 10857
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574934(2-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dih...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574935(2-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dih...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574933(2-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dih...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574936(1-((R)-1-(4-(3-methoxyazetidin-1-yl)cyclohexyl)eth...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574938(7-((R)-1-(4-(3-methoxyazetidin-1-yl)cyclohexyl)eth...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574939(1-((R)-1-(5-(3,3-dimethylazetidin-1-yl)-1,3-dioxan...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574941(1-((R)-1-(4-((R)-3-fluoropyrrolidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574942(1-((R)-1-(4-((R)-3-fluoropyrrolidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574943(1-((R)-1-(4-(3-fluoro-3-methylazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574944((R)-1-(1-(1-(3,3-difluorocyclobutyl)piperidin-4-yl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574945(7-fluoro-1-((R)-1-(4-(3-fluoroazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574946((R)-6-fluoro-1-(1-(4-(3-fluoroazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574947(5-fluoro-1-((R)-1-(4-(3-fluoroazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574948(5-fluoro-1-((R)-1-(4-(3-fluoroazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574949(1-((R)-1-(5-(3,3-difluoroazetidin-1-yl)-1,3-dioxan...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574953((R)-2-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574954(6-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dih...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574955(1-((R)-1-(4-(3-methoxy-3-methylazetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574956(1-((R)-1-(4-(3-methoxy-3-methylazetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574957(1-((R)-1-(4-(3-ethoxyazetidin-1-yl)cyclohexyl)ethy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574958(1-((R)-1-(4-(3-ethoxyazetidin-1-yl)cyclohexyl)ethy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574959((R)-6-fluoro-2-methyl-N-((6-methyl-4-(methylthio)-...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574960(N-((4-((fluoromethyl)thio)-6-methyl-2-oxo-1,2-dihy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574961(5-fluoro-1-((R)-1-(4-(3-methoxyazetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574963(1-((R)-1-(4-(3,3-difluoropyrrolidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574964(1-((R)-1-(4-(3-(difluoromethyl)azetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574966(5-chloro-1-((R)-1-(4-(3-fluoroazetidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574967(N-((4-(cyclopropylthio)-6-methyl-2-oxo-1,2-dihydro...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574968(1-((R)-1-(4-(3-cyclopropoxyazetidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574970(7-((R)-1-(4-(3-cyclopropoxyazetidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574971(7-((R)-1-(4-(3-cyclopropoxyazetidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574972((R)-4-chloro-2-methyl-N-((6-methyl-4-(methylthio)-...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574976(5-chloro-1-((R)-1-(4-(3-methoxyazetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574977(5-chloro-1-((R)-1-(4-(3-methoxyazetidin-1-yl)cyclo...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574978(5-chloro-1-((R)-1-(4-((R)-3-fluoropyrrolidin-1-yl)...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574979(7-((R)-1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM50541897(CHEMBL4634390 | US11459315, Example 109)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574981(2-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dih...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574982(1-((1R)-1-(4-(3-cyclopropoxypyrrolidin-1-yl)cycloh...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574985(1-((R)-1-(4-(3-cyclopropoxyazetidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574983(1-((R)-1-(4-(3-(tert-butoxy)azetidin-1-yl)cyclohex...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574984(1-((R)-1-(4-(3-(tert-butoxy)azetidin-1-yl)cyclohex...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574986(1-((R)-1-(4-(3-cyclopropoxyazetidin-1-yl)cyclohexy...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574988(1-((R)-1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574989(1-((R)-1-(4-(3-(2,2-difluoroethoxy)azetidin-1-yl)c...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574991(1-((R)-1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574992(1-((R)-1-(4-((R)-3-(difluoromethoxy)pyrrolidin-1-y...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574993(1-((R)-1-(4-((S)-3-(difluoromethoxy)pyrrolidin-1-y...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574994(1-((R)-1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetHistone-lysine N-methyltransferase EZH2(Homo sapiens (Human))
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM574996(1-((R)-1-(4-(3-(difluoromethoxy)azetidin-1-yl)cycl...)
Affinity DataIC50:  0.5nMAssay Description:Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM PRC2 containing wt EZH2 (pentame...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 228 total ) | Next | Last >>
Jump to: